A Phase 1, First-in-Human, Dose Escalation Study of JNJ-88998377 in Participants with Relapsed/Refractory B-cell NHL

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509258-71-00

Acronym

88998377LYM1001

Enrollment

Registered

2024-07-03

Start date

2024-07-24

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relapsed or refractory B‑cell non-Hodgkin lymphomas

None listed

Sex/Gender

All

Age

18 Years to No maximum

Italy, Poland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026